Clinical Trial Details (PDF Generation Date :- Thu, 16 Sep 2021 19:48:43 GMT)

CTRI Number	CTRI/2020/05/025346 [Registered on: 25/05/2020] - **Trial Registered Prospectively**
Last Modified On	25/05/2020
Post Graduate Thesis	No
Type of Trial	Interventional
Type of Study	Biological
Study Design	Randomized, Parallel Group Trial
Public Title of Study	A Clinical Trial to Assess the Safety and Efficacy of Convalescent Plasma in Severe Covid-19 patients.
Scientific Title of Study	A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma in Severe Covid-19 patients.

Secondary IDs if Any

Secondary ID	Identifier
Form CT-06, No. CT/BP/07/2020	DCGI

Details of Principal Investigator or overall Trial Coordinator (multi-center study)

Details of Principal Investigator	
Name	Dr Latha B
Designation	Associate Professor
Affiliation	Rajiv Gandhi Government General Hospital, Madras Medical College,
Address	Department of Transfusion Medicine, Rajiv Gandhi Government General Hospital, Madras Medical College, Chennai AJ 45, 9th main road, shanthi colony, Annanagar, Chennai-40 Chennai TAMIL NADU 600003 India
Phone	9840313152
Fax	
Email	latsbalu@yahoo.co.uk

Details Contact Person (Scientific Query)

Details Contact Person (Scientific Query)	
Name	Dr S Anbuselvi Mattuvar Kuzhali
Designation	Assistant Professor of physiology
Affiliation	Madras Medical College,
Address	Institute of Physiology and Experimental Medicine, Madras Medical College, Chennai 4B, third floor, KGEYES HYACINTH, LB road, Kamaraj Nagar, Thiruvanmiyur, Chennai Chennai TAMIL NADU 600003 India
Phone	9940840760
Fax	
Email	dranbuselvimk@gmail.com

Details Contact Person (Public Query)

Details Contact Person (Public Query)	
Name	DrJAYANTHI RANGARAJAN
Designation	DEAN
Affiliation	Rajiv Gandhi Government General Hospital, Madras Medical College,
Address	Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai 6A Sagath Srinivas 2nd Street Srinivasapuram Thiruvanmiyur 600041 Chennai

	Chennai TAMIL NADU 600003 India
Phone	9840025339
Fax	
Email	rjayanthi363@gmail.com

Source of Monetary or Material Support

Source of Monetary or Material Support
> Secretariat, Government of Tamilnadu, Namakkal Kavignar Maaligai, Fort St. George,Chennai 600 009

Primary Sponsor

Primary Sponsor Details	
Name	Government of TamilNadu
Address	Health and Family Welfare Secretariat Chennai 600009
Type of Sponsor	Government medical college

Details of Secondary Sponsor

Name	Address
NIL	NIL

Countries of Recruitment

List of Countries
India

Sites of Study

Name of Principal Investigator	Name of Site	Site Address	Phone/Fax/Email
Dr S Subash	Rajiv Gandhi Government General Hospital Madras Medical College	Room.No.204 Tower Block 2, ground floor, Department of Transfusion Medicine & Covid acute care facility Rajiv Gandhi Government General Hospital Madras Medical College Chennai Chennai TAMIL NADU	9381715141 dchsub@yahoo.co.in

Details of Ethics Committee

Name of Committee	Approval Status	Date of Approval	Is Independent Ethics Committee?
Institutional ethics committee, Madras Medical College	Approved	14/05/2020	No

Regulatory Clearance Status from DCGI

Status	Date
Approved/Obtained	29/04/2020

Health Condition / Problems Studied

Health Type	Condition
Patients	Coronavirus as the cause of diseases classified elsewhere

Intervention / Comparator Agent

Type	Name	Details
Comparator Agent	Control Arm	In control arm are 30 participants who are severe Covid patients being treated in acute care facility and who will be receiving only the standardized acute care treatment for the disease
Intervention	Treatment Arm	In treatment arm are 30 participants who are severe

		Covid patients being treated in acute care facility, apart from receiving standardized acute care treatment, they will also be transfused, initially with one unit of 200ml of ABO compatible convalescent plasma and subsequent dose of 200ml after 24 hours of the initial dose.

Inclusion Criteria

Inclusion Criteria	
Age From	20.00 Year(s)
Age To	50.00 Year(s)
Gender	Both
Details	A. INCLUSION CRITERIA FOR DONOR: Convalescent plasma: Eligibility of Donor Potential donors will include the following: 1. Prior diagnosis of COVID-19 documented by a laboratory test , treated and completely recovered from Covid infection. 2. Complete resolution of symptoms and at least one negative lab test for Covid-19 at least 28 days prior to donation (as per NBTC guidelines after Covid -19 pandemic for donor selection). 3. If plasma is collected prior to 28 days after full recovery from illness, then confirmation of the resolution of the infection should be obtained through demonstration of two nasopharyngeal swab tests for SARS-CoV-2 performed at an interval of at least 24 hours on nasopharyngeal swabs. These individuals will be contacted telephonically and explained the details of the study and their extent of participation. If requested, they will be provided transport for the same. Donor eligibility criteria: The following eligibility criteria will be applied towards potential donors: 1. Only males and nulliparous female donors of weight > 55 kgs will be included. 2. Donor eligibility criteria for whole blood donation as per the departmental SOP will be followed in accordance to the Drugs & Cosmetics Act 1940 and rules 1945 therein (as amended till March 2020). Donor will be screened, followed by brief physical examination. 3. Donors not fit to donate blood based on the history and examination will be deferred and excluded from plasma donor pool for a time period specified by country regulation & departmental SOPs. 4. In addition to the afore mentioned donor eligibility criteria, two EDTA samples (5 ml each) and one plain sample (5 ml) will be drawn for the following pre-donation tests as required for convalescent plasmapheresis (CPP). a) Blood group and antibody screening – Antibody screen positive donors will be deferred. b) Donors with Hb>12.5g/dl, platelet count>1,50,000 per microliter of blood and TLC within normal limits will be accepted. c) Screening for HIV, HBV and HCV by serology or NAT. Donor negative by both the tests will be included. d) Screening for syphilis and malaria by serology. Negative donors will be included e) Total serum protein. Donors with total serum protein > 6gm/dl will be accepted (as per Drugs and Cosmetics (Second Amendment) Rules, 2020) f) Presence of IgG and IgM antibodies to covid-19 by quantification test as per manufacturer’s instruction. Donors negative for these will be deferred. g) Titration of anti-covid-19 (both IgG and IgM) antibodies and SARS-CoV-2 neutralizing antibodies may be done depending on availability of facilities at the time of testing. (Desired titers for IgG antibodies >1024 or neutralizing antibodies >40) doubling dilution of donor serum will be done and titration will be done using CLIA. If not done at the time of plasma collection the donor samples will be stored in aliquots at -80° C to be tested at a later date. h) Molecular test for covid-19 either from

	nasopharyngeal swab specimens may be done depending on availability of tests. Donor's positive will be deferred. B. INCLUSION CRITERIA FOR RECIPIENT OF CCP: 1. Age should be above 20 years for both genders. 2. Covid positive patients who are under treatment in the covid acute care facility, amongst whom are willing to give consent to participate in this study. 3. Should be admitted in the acute care facility for the treatment of Covid-19 infection without complications. 4. Clinical symptoms suggestive of Covid infection along with confirmed laboratory diagnosis of infection with covid-19 as per ICMR/FDA guidelines. 5. Patients should be classified under severe covid-19 infection without complications criteria as judged by the qualified treating physician. Criteria for Severe covid-19 are either one or more of the following: 1. Dyspnea should be present. 2. Respiratory rate ? 30/min 3. Oxygen saturation ? 93% 4. partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300 5. lung infiltrates > 50% within 24 to 48 hours.

Exclusion Criteria

Exclusion Criteria	
Details	EXCLUSION CRITERIA FOR DONOR: Covid-19 infected patients who are under treatment with the criteria: 1. Consecutive 2 swabs positive for covid-19 2. One molecular test for covid-19 positive – RT-PCR. 3. Clinically symptoms suggestive of covid-19. 4. Multiparous female and patient with co morbid conditions. EXCLUSION CRITERIA FOR RECIPIENTS: 1. Patients with any past history of transfusion reactions to blood products. 2. Receipt of Pooled Immunoglobulin in last 30 days 3. Critically ill patients: respiratory failure, Sepsis, Multiorgan failure, Shock (Requiring Vasopressor to maintain a MAP ? 65mmHg or MAP below 65 mmHg) 4. Participating in any other clinical trial 5. Pregnant and lactating women. 6. Patients infected with Covid-19 not under criteria for severe covid condition. 7. Patients with any chronic history of coronary artery disease, coronary bypass surgery, acute pulmonary edema, Pulmonary embolism, Congestive heart failure, Malignant hypertension, Polycythemia Vera, Severe renal failure, Cirrhosis and with any implants.

Method of Generating Random Sequence	Not Applicable
Method of Concealment	Not Applicable
Blinding/Masking	Not Applicable

Primary Outcome

Outcome	Timepoints
To prevent progression to severe ARDS (P/F ratio 100) and all-cause Mortality at 1 month.	Improvement of clinical symptoms and investigations will be monitored daily for first 3 days, and on day 7, 14, 21, 28, once a month till 3 months.

Secondary Outcome

Outcome	Timepoints
Monitoring safety and efficacy pre & post-CCP transfusion: - Duration(Days) of ICU stay/Hospital stay from symptom onset, - Duration of mechanical	After the CCP transfusion, Serious adverse events will be noted on day 0, 3, 7, 14, 21, 28 and once a month upto 3 months.

	ventilation(Invasive/Non-invasive). - Incidence of transfusion reactions, ARDS & sepsis, - Duration of clinical symptoms and Radiological improvement post transfusion - In-hospital mortality, - Levels of IgG antibody,neutralizing antibody titers.
Target Sample Size	**Total Sample Size=**90 **Sample Size from India=**90 **Final Enrollment numbers achieved (Total)=**Applicable only for Completed/Terminated trials **Final Enrollment numbers achieved (India)=**Applicable only for Completed/Terminated trials
Phase of Trial	N/A
Date of First Enrollment (India)	01/06/2020
Date of First Enrollment (Global)	No Date Specified
Estimated Duration of Trial	**Years=**1 **Months=**11 **Days=**30
Recruitment Status of Trial (Global)	Not Applicable
Recruitment Status of Trial (India)	Not Yet Recruiting
Publication Details	not yet.
Brief Summary	**SUMMARY OF STUDY DESCRIPTION:** **This study trial will provide access to convalescent plasma for patients infected with Covid-19 who are classified by**

a qualified physician as severe disease and also to assess the safety and efficacy of the therapy. After getting informed written consent, Patient information sheet and recruitment based on the eligibility protocol for donor / recipient,

(i) CCP will be collected from donor as per the protocol and

(ii) The participants (n=60) are severely ill Covid patients without complications being treated in acute care facility. They will be categorized into 2 (arms) groups –

a.) control group [n=30] in which Covid patients who will be receiving only the standardized acute care treatment for the disease and

b.) study group (n=30) in which Covid patients apart from receiving standardized acute care treatment, who will also be transfused with one unit of 200ml of ABO compatible convalescent plasma and subsequent dose of 200ml after 24 hours of initial dose – which (CCP) will be obtained from the donor who has recovered from documented infection with Covid-19.

Assessment information collected will include the clinical characteristics of the patient plus if any serious adverse events confirmed to be related to the administration of covid convalescent plasma (CCP) from the day of first dose administration with periodical follow-up till 3 months.

<u>Other information to be collected retrospectively and for follow up will include:</u>

(i) Donor: sociodemographic details, clinical characteristics of the recovered patients, Covid test results with antibody titers, investigations and treatment.

(ii) Recipient:

Sociodemographic details,

Covid facility resource utilization: Clinical characteristics of the patients receiving CCP transfusion such as Days of hospital stay and Days in ICU from symptom onset, Days of mechanical ventilation (invasive/non-invasive), Primary symptoms,
associated Comorbidity, In-hospital mortality,
treatment of drugs with all investigations included from the day of admission to the hospital and survival to discharge from the acute

care facility.

Effects of CCP transfusion: Duration of clinical symptoms and Radiological improvement post transfusion, Amelioration of routine laboratory tests for covid disease. Increase in IgG and neutralizing antibody titers and disappearance of Covid-19 RNA.

Transfusion reactions/SAE to Covid Convalescent Plasma from the onset of CCP therapy with periodic follow up for 3months.